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Letters to the Editor
In the article of Butenas et al. (1) like in a number of similar 
publications of these authors on the same subject (2–6), the authors 
observe a relatively good agreement between the behavior of a model
system of the thrombin generating mechanism, reconstructed from a 
set of purified proteins, and the data obtained from clotting whole
blood.
This is an extremely interesting result because it strongly suggests
that the model system realistically represents the essence of the physio-
logical mechanism. If this is true, then the data from the model system
should automatically also have to be in accordance with observations
on thrombin generation in platelet poor and in platelet rich plasma
(PPP/PRP).
Comparison with data obtained by others in PPP and PRP therefore
should be an essential element in the discussion. In the last decade
much new information on thrombin generation in these systems has 
been obtained by various groups [e. g. (7-12), see (13) for more exam-
ples]. However, in the articles of Butenas and coauthors, all references
to recent work on thrombin generation in PPP and PRP are carefully
avoided.
If we do attempt such a comparison, several discrepancies appear:
The most obvious is that thrombin generation in the reconstituted 
system with added procoagulant phospholipids (PS/PC) is about three
times as high as that in normal plasma. Calculation of prothrombin 
conversion and thrombin decay from the curves of fig. 1 from (1) using
the figures for the concentrations previously published (4) and the 
algorithm of (14), shows that thrombin is inactivated at about half of the
rate observed in fresh normal citrated plasma [i. e. in the absence of 
heparin, see (15)], despite the presence of purified antithrombin at a
concentration that is about 1.4 times higher than the physiological one
(15, 16). Physiological concentrations of purified proteins obviously do
not guarantee physiological activities. Calculation of prothrombin 
conversion also reveals that the prothrombin present must be (almost)
entirely converted into thrombin. In whole blood, according to the same
authors (17) 25% of prothrombin remains unconverted; in our experi-
ence in PPP and PRP about 10% residual prothrombin remains. Under
near to physiological conditions prothrombinase activity therefore
stops before its substrate, i. e. prothrombin, is exhausted. In the recon-
stituted system it does not, despite the presence of TFPI, protein C and
thrombomodulin. In normal PPP, even without added TM, the APC 
system effectively limits the amount of prothrombin converted, as can
be judged from the fact that more thrombin is generated in APC 
resistant plasma than in normal plasma (18). Apparently a phenomenon
of recognised pathophysiological importance is not reflected in the 
reconstituted system. This might, for example, be caused by biological
activity of the proteins added and/or the absence of phosphatidyl etha-
nolamine (PE) that is known to be required for protein C activation by
TM (19). Platelets do contain PE, which may (partly) explain why
thrombin generation in the reconstituted system with platelets is so
much lower than with added PCPS (Butenas op. cit. figs 1 and 2).
When comparing observations made in fresh PRP with those in the
reconstituted system with isolated platelets it strikes that thrombin 
formation occurs almost immediately. In fresh PRP (7), and in whole
blood (8), it is characteristically preceded by a lag time of several minu-
tes, also observed in minimally altered whole blood by the authors et al.
(17). During this lag, thrombin mediated reinforcement loops switch on
(7, 20) and in this respcet PRP is fundamentally different from PPP to
which procoagulant phospholipids and TF are added. The mechanism
involves platelet receptors GPIIb/IIIa (21) and GPIb in combination
with von Willebrand Factor (vWF) and fibrin (22). Its physiological
importance is illustrated by the fact that in fresh PRP, thrombin genera-
tion is seriously impaired in von Willebrand disease (independent of the
concomitant lack of factor VIII) as well as in congenital a- and hypo-
fibrinaemia (13, 22). Due comparison to pre-existent literature would
have learned that the lag-time tends to disappear when isolated platelet
are added back to plasma [cf. figures 5 and 3 in (21)] and gradually dis-
appears by the addition of traces of thrombin or of TF concentrations
equal to or higher than that in human brain thromboplasin diluted 1:240
(7), a dilution that roughly corresponds to the 15 pM used by Butenas 
et al. Probably slight platelet damage during isolation, or TF concentra-
tions above a certain very low level, generates sufficient thrombin to
short-circuit one or more of the physiological mechanisms that trigger
platelet procoagulant activity. This explains why the activity of the 
reconstituted system has a superficial resemblance to normal function
even in the absence of fibrinogen and von Willebrand factor.
It is known for over half of a century – and reconfirmed in the 
present article – that the platelet number does not influence the clotting
time of blood unless below 10% of normal e. g. (23). Extensive expe-
riments on the relation between platelet number and thrombin genera-
tion in fresh or reconstituted PRP exist in the literature (21, 24). From
these results one can deduce that only a small amount of the platelet
procoagulant material is required for the onset of thrombin generation.
In our experience, even in citrated or ACD PRP, the minimal platelet
damage that suffices to facilitate thrombin generation already is observ-
able within two hours after venapuncture. A fortiori, in thrombin 
generation experiments in which isolated platelets are used, one has to
reckon with such damage and a control that determines how much 
procoagulant phospholipids are present in the unactivated platelet prep-
aration is obligatory. In summary: Maintenance of the claim that the 
results in the model system of Butenas et al. represent more than a 
superficial similarity to a physiologically relevant situation would 
require careful comparison to the body of knowledge on thrombin 
generation in PPP, PRP and blood as built up in recent years by other
groups, as well as control experiments that show 1: Normal activity of
the thrombin inhibiting system; 2: Normal activity of the TM-protein C
system; 3: Normal activity of the TFPI system; 4: An estimate of 
procoagulant phospholipids present in the platelet preparation used and
5: Dependency of the system on vWF and fibrinogen.
Thrombin Generation in a Reconstituted System: A Comment
Thromb Haemost 2002; 87: 551–2
Correspondence to: Prof. H. C. Hemker, Cardiovascular Research 
Institute, Maastricht University, Universiteitssingel 50, P. O. Box 616, 
NL-6200 MD, Maastricht, The Netherlands – Tel.: +31 43 388 1674/75, 
Fax: +31 43 388 4759; E-mail: HC.Hemker@thrombin-com
552
Letters to the Editor
H. Coenraad Hemker
Cardiovascular Research Institute Maastricht, Maastricht University,
The Netherlands
References
1. Butenas S, Branda RF, van’t Veer C, Cawthern KM, Mann KG. Platelets
and phospholipids in tissue factor-initiated thrombin generation. Thromb
Haemost 2001; 86: 660-7.
2. Cawthern KM, van’t Veer C, Lock JB, DiLorenzo ME, Branda RF, 
Mann KG. Blood coagulation in hemophilia A and hemophilia C. Blood
1998; 91: 4581-92.
3. Mann KG, van’t Veer C, Cawthern K, Butenas S. The role of the tissue 
factor pathway in initiation of coagulation. Blood Coagul Fibrinolysis
1998; 9 Suppl 1: S 3-7.
4. Butenas S, van’t Veer C, Mann KG. “Normal” thrombin generation. 
Blood 1999; 94: 2169–78.
5. Butenas S, van’t Veer C, Cawthern K, Brummel KE, Mann KG. Models of
blood coagulation. Blood Coagul Fibrinolysis 2000; 11 Suppl 1: S9-13.
6. Butenas S, Cawthern KM, van’t Veer C, DiLorenzo ME, Lock JB, Man
KG. Antiplatelet agents in tissue factor-induced blood coagulation. Blood
2001; 97: 2314-22.
7. Beguin S, Lindhout T, Hemker HC. The effect of trace amounts of tissue
factor on thrombin generation in platelet rich plasma, its inhibition by 
heparin. Thromb Haemost 1989; 61: 25-9.
8. Kessels H, Beguin S, Andree H, Hemker HC. Measurement of thrombin 
generation in whole blood-the effect of heparin and aspirin. Thromb 
Haemost 1994; 72: 78-83.
9. Prasa D, Svendsen L, Sturzebecher J. Inhibition of thrombin generation in
plasma by inhibitors of factor Xa. Thromb Haemost 1997; 78: 1215-20.
10. Prasa D, Svendsen L, Sturzebecher J. The ability of thrombin inhibitors to
reduce the thrombin activity generated in plasma on extrinsic and intrinsic
activation. Thromb Haemost 1997; 77: 498-503.
11. Herault JP, Dol F, Gaich C, Bernat A, Herbert JM. Effect of clopidogrel on
thrombin generatin in platelet-rich plasma in the rat. Thromb Haemost
1999; 81: 957-60.
12. Peyrou V, Lormeau JC, Herault JP, Gaich C, Pfliegger AM, Herbert JM.
Contribution of erythrocytes to thrombin generation in whole blood.
Thromb Haemost 1999; 81: 400-6.
13. Hemker HC, Beguin S. Phenotyping the clotting system. Thromb Haemost
2000; 84: 747-51.
14. Hemker HC, Willems GM, Beguin S. A computer assisted method to obtain
the prothrombin activation velocity in whole plasma independent of throm-
bin decay processes. Thromb Haemost 1986; 56: 9-17.
15. Beguin S, Kessels H, Dol F, Hemker HC. The consumption of antithrombin
III during coagulation, its consequences for the calculation of prothrom-
binase activity and the standardisation of heparin activity. Thromb Haemost
1992; 68: 136-42.
16. Conard J, Brosstad F, Lie Larsen M, Samama M, Abildgaard U. Molar 
antithrombin concentration in normal human plasma. Haemostasis 1983;
13: 363-8.
17. Rand MD, Lock JB, van’t Veer C, Gaffney DP, Mann KG. Blood clotting
in minimally altered whole blood. Blood 1996; 88: 3432-45.
18. Nicolaes GA, Thomassen MC, Tans G, Rosing J, Hemker HC. Effect of 
activated protein C on thrombin generation and on the thrombin potential in
plasma of normal and APC-resistant individuals. Blood Coagul Fibrinolysis
1997; 8: 28-38.
19. Smirnov MD, Ford DA, Esmon CT, Esmon NL. The effect of membrane
composition on the hemostatic balance. Biochemistry 1999; 38: 3591-8.
20. Biggs R, Macfarlane RG. Human Blood Coagulation. Blackwell Scientific
Publications 1953; p. 97.
21. Reverter JC, Beguin S, Kessels H, Kumar R, Hemker HC, Coller BS. 
Inhibition of platelet-mediated, tissue factor-induced thrombin generation
by the mouse/human chimeric 7E3 antibody. Potential implications for the
effect of c7E3 Fab treatment on acute thrombosis and “clinical restenosis”.
J Clin Invest 1996; 98: 863-74.
22. Beguin S, Kumar R, Keularts I, Seligsohn U, Coller BS, Hemker HC. 
Fibrin-dependent platelet procoagulant activity requires GPIb receptors and
von Willebrand Factor. Blood 1999; 93: 64-70.
23. Eagle H. Studies on Blood Coagulation. I. The role of Prothrombin and of
Platelets in the Formation of Thrombin. J Gen Physiol 1934; 18: 531-45.
24. Galli M, Beguin S, Lindhout T, Hemker CH. Inhibition of phospholipid and
platelet-dependent prothrombinase activity in the plasma of patients with
lupus anticoagulants. Br J Haematol 1989; 72: 549-55.
Received October 18, 2001 Accepted October 25, 2001
Thrombin Generation in a Reconstituted System: A Reply
Thromb Haemost 2002; 87: 552–4
Correspondence to: Kenneth G. Mann, Department of Biochemistry, 
University of Vermont, Given Building Room C401, 89 Beaumont Avenue,
Burlington, VT 05405-0068, USA – Tel.: 802-656-0335; Fax: 802-862-8229;
E-mail: kmann@zoo.uvm.edu
Dear Sir,
The aim of our laboratory is to provide a biologically relevant, 
quantitative, mechanistic description of the blood coagulation process.
Toward this end, we have developed two biological systems, which 
involve non-anticoagulated, non-chilled whole human blood: a) 
Phlebotomy blood contact pathway suppressed by corn trypsin inhibitor
is initiated to clot in vitro by a fixed concentration of a chemically 
defined tissue factor (TF) preparation (1-6); b) Blood exuding from 
a microvascular wound is evaluated for composition by sequential 
sampling (7, 8). 
We attempt to emulate these biological models using mixtures of
highly purified reaction components and examine the individual and
combined mechanistic contributions of substrates, intermediates and
products in the reaction (6, 9-17). Finally, we simulate these reactions
using computer-based models employing defined chemical parameters
for the individual reactions of the blood coagulation process and its 
regulation (18, 19). Each person has an individual phenotype which
may or may not represent mean population values either quantitatively
or qualitatively. Therefore we use convergence of results from biological,
